MAPK Inhibitors Restore CAR T-Cell Target in Thyroid Cancer Models - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

MAPK Inhibitors Restore CAR T-Cell Target in Thyroid Cancer Models

Trametinib and dabrafenib increased TSHR expression and improved the activity of CAR T cells in a patient-derived model of anaplastic thyroid cancer

  • September 24, 2026

  • 3 min

Share

Original Source(s)

MAPK Inhibitors Restore CAR T-Cell Target in Thyroid Cancer Models

  • September 24, 2026

Related Content

Multicentre evaluation of artificial intelligence risk classification for detection of clinically significant prostate cancer on biparametric MRI

Decoding cancer-associated ribosomal protein mutations: A new frontier in cancer and ribosome biology

Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study